CLINICAL RESEARCH ON DRUG ABUSE

药物滥用的临床研究

• 批准号: 6174517
• 负责人: Eric C. Strain
• 金额: $ 12.79万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-01 至 2002-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6174517
• 关键词: behavior therapy; behavioral /social science research tag; buprenorphine; clinical research; clinical trials; cocaine; combination chemotherapy; counseling; dosage; drug abuse; drug abuse chemotherapy; drug abuse prevention; drug administration routes; health services research tag; heroin; human subject; human therapy evaluation; naloxone; outcomes research; pharmacokinetics; relapse /recurrence; tryptophan

DESCRIPTION: (Applicant's Abstract) This is an application for a KO2 Independent Scientist Award (ISA) from the National Institute on Drug Abuse. The applicant is Eric Strain, a physician-researcher in the Department of Psychiatry at Johns Hopkins University School of Medicine. Dr. Strain has devoted his career to research on drug abuse and to treatment of substance abusing patients, with his primary interest focused upon the development of medications for the treatment of opioid and cocaine dependence. This work has included human laboratory studies as well as clinical trials testing the efficacy of medications for the treatment of substance abuse disorders. There are six short-term and two long-term career goals that will be accomplished through the support provided by this ISA. Short-term career goals are: 1) to conduct clinical pharmacology and treatment-evaluation research pertinent to the development of medications for the treatment of substance abuse disorders, 2) to study medication combinations being developed for the treatment of substance abuse disorders, 3) to develop methodologies integrating pharmacotherapies with behavioral therapies in clinical trials of substance abuse treatments, 4) to study treatment approaches for patients with combined opioid and cocaine dependence, 5) to develop expertise in the development process of new medications for the treatment of substance abuse disorders, and 6) to regularly present results from studies at scientific meetings, in peer-reviewed journals, and to the treatment community. Achieving these short-term goals will contribute to accomplishing the first long-term goal, to become a recognized expert in drug abuse, its treatment, and research issues related to the study of substance abuse. In addition, a second long-term goal is to serve as a mentor to young scientists, and especially function as a role model for young physicians interested in pursuing a career in substance abuse research. The Research Plan included in this application provides illustrative investigations that provide a mechanism for achieving the career goals described. These studies examine the pharmacological effects of buprenorphine/naloxone combinations in human laboratory studies, and test a novel pharmacotherapy combined with a known and effective behavioral therapy in an outpatient clinical trial treating cocaine dependence. This research will be conducted through the Behavioral Pharmacology Research Unit (BPRU), a component of the Hopkins Department of Psychiatry. Dr. Strain has the strong support of the BPRU, the Department of Psychiatry, and the Hopkins School of Medicine, and this ISA provides a mechanism for ensuring the continuation of his highly productive career in substance abuse research. Thus, this ISA represents a good investment by NIDA.

描述：（申请人摘要） 这是KO 2独立科学家奖（伊萨）的申请， 国家药物滥用研究所。 申请人是Eric Strain， 约翰霍普金斯大学精神病学系的一位医生兼研究员 大学医学院。 斯特兰博士把他的职业生涯都奉献给了 研究药物滥用和治疗药物滥用患者， 他的主要兴趣集中在药物的发展， 阿片类药物和可卡因依赖的治疗。 这项工作包括人类 实验室研究以及临床试验测试的功效 用于治疗物质滥用障碍的药物。 有六 短期和两个长期的职业目标，将通过 这是伊萨提供的支持。 短期职业目标是：1） 开展与以下方面相关的临床药理学和治疗评价研究 药物滥用治疗药物的开发 2）正在开发的研究药物组合， 药物滥用病症的治疗，3）制定方法 将药物疗法与行为疗法相结合 药物滥用治疗临床试验中的治疗，4）研究 阿片类药物和可卡因联合使用患者的治疗方法 5）在新的发展过程中发展专业知识 用于治疗物质滥用障碍的药物，以及6） 定期在科学会议上介绍研究结果， 同行评审期刊和治疗社区。 实现这些 短期目标将有助于实现第一个长期目标， 成为药物滥用，治疗和研究方面的公认专家 与药物滥用研究有关的问题。 此外，第二 长期目标是作为青年科学家的导师，特别是 作为一个年轻的医生有兴趣追求一个榜样， 从事药物滥用研究 本研究计划包括 应用程序提供了说明性的调查，提供了一种机制， 实现所描述的职业目标。 这些研究考察了 丁丙诺啡/纳洛酮组合在人体中的药理学作用 实验室研究，并测试一种新的药物疗法与已知的 和有效的行为疗法在门诊临床试验治疗 可卡因依赖 这项研究将通过行为 药理学研究单位（BPRU），霍普金斯医学部的一个组成部分， 精神病学。 Strain博士得到了BPRU的大力支持 精神病学和霍普金斯医学院，这个伊萨提供了一个 确保他继续从事卓有成效的职业生涯的机制， 药物滥用研究 因此，该伊萨是一项良好的投资， 妮达